



Disclaimer

- This presentation may contain certain forward-looking statements, including assumptions, opinions and views of the Company or cited from third party sources. Various known and unknown risks, uncertainties and other factors could cause the actual results, financial position, development or performance of the Company to differ materially from the estimations expressed or implied herein.
- The Company does not guarantee that the assumptions underlying such forward-looking statements are free from errors nor does the Company accept any responsibility for the future accuracy of the opinions expressed in this presentation or the actual occurrence of the forecast development.
- No representation or warranty (express or implied) is made as to, and no reliance should be placed on, any information, including projections, estimates, targets and opinions, contained herein, and no liability whatsoever is accepted as to any errors, omissions or misstatements contained herein, and, accordingly, none of the Company or any of its parent or subsidiary undertakings or any of such person's officers, directors or employees accepts any liability whatsoever arising directly or indirectly from the use of this document.



Agenda

■ Review Q2 2011 and Guidance FY 2011

Uwe Röhrhoff, CEO


■ Financial Overview Q2 2011

Jürgen Wiecha, CFO

Appendix



Q2 2011: Strong quarter despite some headwinds





Q2 2011: Operational key facts

Tubular Glass:

- Technical changes and revalidations of the RTF® lines successfully completed
- Furnace overhaul completed as scheduled

Plastic Systems:

- Strong growth across all product categories
- Integration of Vedat successfully started
- Growing MPS unit: Doubling of production area in the Czech Republic
- ➤ Growth market diabetes: Commercial production of "ClikSTAR®" insulin pen for Sanofi

Moulded Glass:

- Strong quarter in revenues and earnings despite furnace overhaul
- Growth of pharma and cosmetics business
- High capacity utilization and efficiency levels

Life Science Research:

- Good revenue growth on a constant fx basis
- Catch-up effects after a muted Q1 2011



Confirmation of Guidance 2011

FY 2010 as reported¹

Guidance FY 2011 (as of Feb. 10, 2011)

Confirmed Guidance 2011 (as of July 13, 2011)

Net revenues

EUR 1,024.8m

+3% to 4% at const. FX

+6% to 7%² at const. FX

Adj. EBITDA margin

20.0%

About 20.0%

About 20.0%

Capex

EUR 73.2m

About EUR 80m

About EUR 80m

¹ FY 2010 average exchange rate: EUR 1.00 = USD 1.34

² Including the acquisition of Vedat as of March 21, 2011



Agenda

Review Q2 2011 and Guidance FY 2011

Uwe Röhrhoff, CEO

■ Financial Overview Q2 2011

Jürgen Wiecha, CFO

Appendix



P&L: Strong operational performance drives adjusted EPS

	Q2 2011 EUR m	Q2 2010 EUR m	Change in %
Total revenues	284.5	268.8	+5.9
Adjusted EBITDA ¹	56.3	56.3	unchanged
EBITDA	55.0	52.7	+4.4
Depreciation and amortization of FV adjustments	24.6	27.9	-11.8
Profit before interest and taxes (EBIT)	30.4	24.8	+22.6
Financial result	-13.3	-9.1	+46.2
Profit before taxes	17.1	15.7	+8.9
Net income	13.3	11.2	+18.8
EPS in EUR	0.38	0.38	unchanged
Adjusted EPS in EUR ²	0.69	0.59	+16.9

 ¹ Earnings before financial result, income taxes, amortization of fair value adjustments, extraordinary depreciation, depreciation and amortization, restructuring expenses and one-off income and expenses
 ² Adjusted net income after non-controlling interests divided by 31.4m shares



Q2 2011: Revenues by division

	Q2 2011		
	EUR m	Change in %	Change in % at const. FX
Total Group	284.5	+5.9	+7.6
Tubular Glass	81.8	-5.0	-1.7
Plastic Systems	98.0	+20.1	+19.0
Moulded Glass	85.2	+4.7	+6.4
Life Science Research	23.4	-0.7	+7.0



Q2 2011: Adjusted EBITDA¹ and margin by division

	Q2 2011			Q2 2010
	EUR m	Change in %	Margin	Margin
Total Group	56.3	unchanged	19.8	20.9
Tubular Glass	16.9	-20.7	20.7	24.9
Plastic Systems	23.5	+15.2	23.9	25.0
Moulded Glass	18.1	+10.2	21.2	20.2
Life Science Research	3.0	+13.0	12.7	11.0

¹ Earnings before financial result, income taxes, amortization of fair value adjustments, extraordinary depreciation, depreciation and amortization, restructuring expenses and one-off income and expenses




Key financial figures

	May 31, 2011 EUR m	May 31, 2010 EUR m	Change in %
Equity Equity ratio in %	536.5 <i>36.4</i>	493.4 36.0	+8.7
Net Working Capital ¹ in % of LTM revenues	171.6 <i>16.</i> 3	202.3 20.4	-15.2
Net Financial Debt ²	404.6	408.7	-1.0
Adj. EBITDA Leverage	1.9	2.1	-9.5
	Q2 2011 EUR m	Q2 2010 EUR m	Change in %
Capital expenditure	24.2	13.6	+77.9
Free cash flow	14.8 ³	12.2	+21.3

 ¹ Inventories (incl. prepayments) and trade receivables less trade payables and payments received on account of orders
 ² Total amount of interest-bearing debt less cash and cash equivalents
 ³ Excluding the preliminary purchase price for the acquisiton of Vedat



Successful refinancing increases financial leeway





Financial calendar

October 6, 2011

Interim Report 3rd Quarter 2011



Investor Relations & Creditor Relations contact details

■ **Phone** +49 211 6181-257

■ **Fax** +49 211 6181-121

■ E-mail gerresheimer.ir@gerresheimer.com

■ IR website www.gerresheimer.com/ir



Agenda

Review Q2 2011 and Guidance FY 2011

Uwe Röhrhoff, CEO

■ Financial Overview Q2

Jürgen Wiecha, CFO

Appendix



Q2 2011 Reconciliation from adjusted EBITDA to net income

	Q2 2011 EUR m	Q2 2010 EUR m
Adjusted EBITDA	56.3	56.3
Restructuring expenses	0.0	3.1
One-off income/expense	1.3	0.5
EBITDA	55.0	52.7
Amortization of fair value adjustments	4.7	6.5
Depreciation	19.9	21.4
Result from operations	30.4	24.8
Financial result	-13.3	-9.1
Income taxes	-3.8	-4.5
Net income	13.3	11.2
Attributable to non-controlling interests	1.2	-0.6
Attributabe to GX shareholders	12.1	11.8
Adjusted net income	22.8	17.9



Q1-Q2 2011 P&L overview

	Q1-Q2 2011 EUR m	Q1-Q2 2010 EUR m	Change in %
Total revenues	521.2	493.6	+5.6
Adjusted EBITDA ¹	98.0	94.6	+3.6
EBITDA	96.6	90.5	+6.7
Depreciation and amortization of FV adjustments	49.5	53.4	-7.3
Profit before interest and taxes (EBIT)	47.1	37.1	+27.0
Financial result	-20.2	-18.0	+12.2
Profit before taxes	26.9	19.1	+40.8
Net income	20.3	13.6	+49.3
EPS in EUR	0.58	0.44	+31.8
Adjusted EPS in EUR ²	0.99	0.81	+22.2

¹ Earnings before financial result, income taxes, amortization of fair value adjustments, extraordinary depreciation, depreciation and amortization, restructuring expenses and one-off income and expenses

² Adjusted net income after non-controlling interests divided by 31.4m shares



Q1-Q2 2011 Revenues by division

	Q1-Q2 2011		
	EUR m	Change in %	Change in % at const. FX
Total Group	521.2	+5.6	+5.4
Tubular Glass	148.7	-5.3	-4.7
Plastic Systems	170.1	+16.3	+14.5
Moulded Glass	165.4	+7.6	+8.0
Life Science Research	44.7	+1.6	+3.0



Q1-Q2 2011 Adjusted EBITDA¹ and margin by division

	Q1-Q2 2011			Q1-Q2 2010
	EUR m	Change in %	Margin	Margin
Total Group	98.0	+3.6	18.8	19.2
Tubular Glass	30.7	-19.3	20.7	24.2
Plastic Systems	37.9	+12.1	22.3	23.1
Moulded Glass	34.2	+21.3	20.7	18.3
Life Science Research	5.2	+17.5	11.6	10.0

¹ Earnings before financial result, income taxes, amortization of fair value adjustments, extraordinary depreciation, depreciation and amortization, restructuring expenses and one-off income and expenses



Q1-Q2 2011 Reconciliation from adjusted EBITDA to net income

	Q1-Q2 2011 EUR m	Q1-Q2 2010 EUR m
Adjusted EBITDA	98.0	94.6
Restructuring expenses	0.0	3.6
One-off income/expense	1.4	0.5
EBITDA	96.6	90.5
Amortization of fair value adjustments	9.4	12.8
Depreciation	40.1	40.6
Result from operations	47.1	37.1
Financial result	-20.2	-18.0
Income taxes	-6.6	-5.5
Net income	20.3	13.6
Attributable to non-controlling interests	2.1	-0.1
Attributabe to GX shareholders	18.2	13.7
Adjusted net income	33.2	25.2